Lefisyo

Levomethadone Hydrochloride, the active ingredient in Lefisyo, is an opioid analgesic presented as an oral formulation for oral use. It is employed in the management of moderate to severe pain and in the treatment of opioid dependence in adult patients.

GNH USA supplies Lefisyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomethadone Hydrochloride acts on the mu‑opioid receptor pathway to provide analgesia and support opioid substitution therapy. - Pain management: reduces moderate to severe chronic pain when other analgesics are insufficient. - Opioid dependence treatment: facilitates withdrawal management and maintenance therapy in individuals with opioid use disorder. - Post‑operative analgesia: provides short‑term pain relief following surgical procedures.

Levomethadone Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel motility. - Drowsiness: increased sleepiness. - Dizziness: light‑headed sensation. - Dry mouth: reduced salivation. - Sweating: excessive perspiration.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, potentially life‑threatening. - Cardiac arrhythmia: irregular heart rhythm, including QT prolongation. - Severe hypotension: marked drop in blood pressure. - Seizures: convulsive episodes. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Levomethadone Hydrochloride, clinicians should consider several safety measures. - Assess respiratory function: monitor for signs of respiratory depression, especially in opioid‑naïve patients. - Evaluate cardiac risk: obtain baseline ECG to detect QT interval prolongation. - Review concomitant CNS depressants: avoid or adjust doses when combined with benzodiazepines or alcohol. - Monitor liver function: adjust dosing in hepatic impairment. - Educate patients on dependence: discuss risks of tolerance and addiction. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Levomethadone Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other opioids: additive respiratory depression. - CNS depressants (e.g., benzodiazepines, barbiturates): heightened sedation and respiratory risk. - QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics): increased risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise levomethadone plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug concentration. - Anticholinergic drugs: may exacerbate constipation.